Last reviewed 2026-04-23 · How we verify

Peginterferon alpha-2a + Ribavirin

Peginterferon alpha-2a + Ribavirin is a Antiviral Small molecule drug developed by Casa Sollievo della Sofferenza IRCCS. It is currently in Phase 3 development for Chronic hepatitis C, Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6. Also known as: Peginterferon alpha-2a (40 kD) PEGASYS, Copegus or Rebetol, Ribavirin Teva.

Peginterferon alpha-2a is a recombinant form of interferon-alpha-2a, which is a protein that helps to stimulate the body's immune response to viral infections, while Ribavirin is an antiviral medication that inhibits viral replication.

Peginterferon alpha-2a is a recombinant form of interferon-alpha-2a, which is a protein that helps to stimulate the body's immune response to viral infections, while Ribavirin is an antiviral medication that inhibits viral replication. Used for Chronic hepatitis C, Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6.

At a glance

Mechanism of action

Peginterferon alpha-2a works by binding to the interferon-alpha receptor on the surface of cells, triggering a signaling cascade that activates the immune system to produce antiviral proteins and cytokines. Ribavirin, on the other hand, is a nucleoside analog that inhibits the replication of viral RNA by causing chain termination during viral RNA synthesis.

Approved indications

• Chronic hepatitis C
• Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6

Common side effects

• Fatigue
• Headache
• Pyrexia
• Nausea
• Diarrhea

Key clinical trials

• Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin
• Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (EARLY_PHASE1)
• Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (PHASE2)
• Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients (NA)
• Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) (PHASE3)
• Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients (PHASE2)
• Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV (PHASE4)
• Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Peginterferon alpha-2a + Ribavirin CI brief — competitive landscape report
• Peginterferon alpha-2a + Ribavirin updates RSS · CI watch RSS
• Casa Sollievo della Sofferenza IRCCS portfolio CI

Frequently asked questions about Peginterferon alpha-2a + Ribavirin

Related

• Drug class: All Antiviral drugs
• Manufacturer: Casa Sollievo della Sofferenza IRCCS — full pipeline
• Therapeutic area: All drugs in Infectious Diseases
• Indication: Drugs for Chronic hepatitis C
• Indication: Drugs for Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6
• Also known as: Peginterferon alpha-2a (40 kD) PEGASYS, Copegus or Rebetol, Ribavirin Teva
• Compare: Peginterferon alpha-2a + Ribavirin vs similar drugs
• Pricing: Peginterferon alpha-2a + Ribavirin cost, discount & access